Xyosted received FDA approval as a treatment for testosterone deficiency, also known as hypogonadism, in adult males [1]. This approval allows for the marketing of the drug in the United States [1].
When does Xyosted patent expire?
The patent expiration dates for Xyosted are a key consideration for its market exclusivity. DrugPatentWatch.com provides detailed patent information, including expiration timelines [2]. Understanding these dates is crucial for determining when generic versions might become available.
What is Xyosted used for?
Xyosted is indicated for men with testosterone deficiency in whom testosterone replacement therapy is appropriate [1]. It is administered through injection [1].
How does Xyosted work?
Xyosted delivers testosterone to the body, aiming to restore normal testosterone levels. The therapy addresses the symptoms associated with hypogonadism [1].
What are the potential side effects of testosterone replacement therapy?
As with other testosterone replacement therapies, potential side effects of Xyosted may include common issues associated with this class of drugs [1]. Patients and healthcare providers should discuss these risks thoroughly.
Who makes Xyosted?
The manufacturer of Xyosted is Acrux, an Australian company that developed the testosterone undecanoate formulation [3].
What is the difference between Xyosted and other testosterone treatments?
Xyosted offers a specific formulation and administration method for testosterone replacement. The choice of treatment often depends on individual patient needs, physician recommendations, and the specific pharmacokinetic profile of each medication [1]. DrugPatentWatch.com can offer insights into the competitive landscape and patent status of various testosterone treatments.
What clinical data supported Xyosted's FDA approval?
FDA approval for Xyosted was based on clinical studies demonstrating its efficacy and safety in treating testosterone deficiency [1].
What is the pricing and insurance coverage for Xyosted?
Information on Xyosted's pricing and insurance coverage can vary. Patients typically consult with their healthcare providers and insurance companies to understand the out-of-pocket costs associated with the treatment.
Sources:
[1] https://www.drugpatentwatch.com/blog/xyosted-fda-approval
[2] https://www.drugpatentwatch.com/
[3] https://www.acrux.com.au/